AIM ImmunoTech Inc. AIM ImmunoTech develops Ampligen, an RNA-based immune modulator designed to activate TLR3, with its lead clinical focus on late-stage pancreatic cancer.
AIM ImmunoTech Inc. AIM ImmunoTech develops Ampligen, an RNA-based immune modulator designed to activate TLR3, with its lead clinical focus on late-stage pancreatic cancer.